Production (Stage)
Citius Pharmaceuticals, Inc.
CTXR
$0.703
-$0.021-2.90%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -16.16% | -3.92% | -20.27% | -25.18% | -16.87% |
| Total Depreciation and Amortization | 7.52% | 7.72% | 7.87% | 8.03% | 8.13% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -6.06% | 23.65% | 70.16% | 129.15% | 105.57% |
| Change in Net Operating Assets | 243.71% | 177.93% | 57.94% | -5.39% | -302.64% |
| Cash from Operations | 22.30% | 11.78% | 2.96% | -1.74% | -13.41% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 32.29% | 8.96% | -8.17% | 7.88% | 47,823.32% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -218.81% | -218.81% | -218.81% | -- | -- |
| Cash from Financing | 16.05% | -9.28% | -27.89% | -0.81% | 43,983.71% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 24.07% | -16.35% | -52.51% | -4.12% | 38.16% |